CytomX TherapeuticsvsMerck & Company

CTMX and MRK stock compared: price, dividend, valuation and results, from SEC filings.

CTMX

CytomX Therapeutics, Inc.

$1.94

Value $423M

-2.27%
CTMX's page

MRK

Merck & Company, Inc.

$143.37

Value $354B

-0.75%
MRK's page

CytomX Therapeutics (CTMX) has a market value of $423M and Merck & Company (MRK) $354B. Over the last year, with dividends, CTMX moved -50.0% and MRK +58.8%. Dividend yield: CTMX none, MRK 2.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CTMX$423M

    MRK$354B

    MRK is 838 times CTMX

  • Revenue, 12 months

    CTMX$14M

    MRK$67.4B

    MRK is 4,803 times CTMX

  • Net income, 12 months

    CTMX-$85M

    MRK$2.5B

  • Operating margin

    CTMX-676.5%

    MRK–

  • ROIC

    CTMX-33.7%

    MRK3.9%

    37.6 points apart

  • P/E

    CTMX–

    MRK144.5

  • Dividend yield

    CTMX0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    CTMX-73.7%

    MRK+98.6%

    172.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CTMX-73.8%

MRK+98.6%

010020020222023202420252026
Returns by period
PeriodCTMXWith dividendsMRKWith dividends
1 year since November 14, 2025-50.0%Price -50.0%+58.8%Price +54.3%
3 years since November 17, 2023+47.0%+13.7% a yearPrice +47.0%+54.4%+15.6% a yearPrice +40.9%
5 years since November 16, 2021-73.7%-23.5% a yearPrice -73.7%+98.6%+14.7% a yearPrice +70.5%
10 years since November 17, 2016-83.1%-16.3% a yearPrice -83.1%+225.1%+12.5% a yearPrice +139.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CTMXCytomX TherapeuticsMRKMerck & Company

Valuation

CTMXMRK
Valuation
Price$1.94$143.37
Market value$423M$354B
Enterprise value (EV)$75M$399B
P/E–144.5
P/E, 5-year median–14.8
P/B1.57.9
EV/EBIT–83.7
Free cash flow yield–4.2%

Results and growth

CTMXMRK
Results and growth
Revenue, 12 months$14M$67.4B
Net income, 12 months-$85M$2.5B
Free cash flow, 12 months-$51M$14.7B
Earnings per share, 12 months-$0.50$0.98
Revenue growth, year on year-44.8%1.3%
Revenue growth a year, past+2.2%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

CTMXMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin-676.5%–
Net margin-609.0%3.6%
ROIC-33.7%3.9%
ROE-38.4%5.2%

Balance sheet

CTMXMRK
Balance sheet
Cash$348M$9.7B
Total debt$4.4M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

CTMXMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CTMX or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, CytomX Therapeutics or Merck & Company?

By market value, Merck & Company ($354B) is about 838.1 times CytomX Therapeutics ($423M), at today's prices.

How did CTMX and MRK stock do over the last 10 years?

Since November 17, 2016, CTMX's price moved -83.1% and MRK's +139.6%. With dividends: CTMX -83.1% (-16.3% a year), MRK +225.1% (+12.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, CTMX or MRK?

The dividend yield at today's price is none for CytomX Therapeutics and 2.37% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, CytomX Therapeutics or Merck & Company?

Over the last twelve months, the net margin was -609.0% for CytomX Therapeutics and 3.6% for Merck & Company, and the operating margin -676.5% and –. Revenue was $14M and $67.4B.

Which is the better investment, CytomX Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.